Patents by Inventor Man Sil PARK

Man Sil PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion protein comprising thyrotropin receptor variants and use thereof
    Patent number: 11479596
    Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 25, 2022
    Assignees: YUHAN CORPORATION, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Moo Young Song, Taejin Yoon, Jung-Sun Lee, Byung Hyun Choi, In Hwan Lim, Man Sil Park, Jin-Hyoung Lee, Hyoung Sig Seo, Hyeon Woo Kang, Sung Ho Kim, Eun Jig Lee, Jin Sook Yoon, Cheol Ryong Ku
  • FUSION PROTEIN COMPRISING THYROTROPIN RECEPTOR VARIANTS AND USE THEREOF
    Publication number: 20210221869
    Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.
    Type: Application
    Filed: July 24, 2019
    Publication date: July 22, 2021
    Inventors: Moo Young SONG, Taejin YOON, Jung-Sun LEE, Byung Hyun CHOI, In Hwan LIM, Man Sil PARK, Jin-Hyoung LEE, Hyoung Sig SEO, Hyeon Woo KANG, Sung Ho KIM, Eun Jig LEE, Jin Sook YOON, Cheol Ryong KU